Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Policy and Pricing

Policy and Pricing

Evaluate

Thumbnail
June 30, 2023

Go or no go? Decision day looms for Eisai and Biogen

Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.

Thumbnail
June 23, 2023

Amylyx rebuff sees Europe regulators diverge from the US

Article image
Vantage logo
June 22, 2023

GSK and Pfizer respiratory disease jabs get muted US backing

Article image
Vantage logo
May 17, 2023

Mulling biopharma’s Minority Report moment

Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.

Article image
Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Article image
Vantage logo
May 15, 2023

The waxing and waning of the speedy approval

As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?

Article image
Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.

Article image
Vantage logo
March 21, 2023

Mereo’s regulatory boost means little without a partner

Article image
Vantage logo
March 16, 2023

Biologics look set to lose US drug price negotiation loophole

Article image
Vantage logo
March 10, 2023

Polivy adcom: no overall survival, no problem

A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.

Article image
Vantage logo
March 01, 2023

Lilly bows to the inevitable on insulin price cuts

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up